Terumo Bct Vietnam Co., Ltd. (Vietnam)

The subject engages in producing blood bags and blood separators. As investigated, The Terumo group has entered the Vietnamese market through Representative Office of Terumo Thai Lan in Ho Chi Minh City and Ha Noi City since 1993. Later, the group set up a first manufacturing business - TERUMO VIETNAM CO.,LTD in 2006 in Ha Noi City. In 2012, a trading one - TERUMO VIETNAM MEDICAL EQUIPMENT CO., LTD in Ha Noi City was formed. Until 2013, the group has expanded in Southern region by establishing the company.Based on the group's the GS26 production strategy, the group has been reviewing our entire portfolio in preparation for the launch of GS26. In particular, Costa Rica, Japan, and Asia will form a tri-polar system. Now, the products in blood and cell technologies segment produced in Vietnam are Trima, Blood Bags, Reveos with markets being global. In addition, completed vertical integration and Costa Rica created available capacity +30%.In 2017, the Terumo group had a portfolio restructuring when Terumo Corporation disposed a whole shareholding in the company to Terumo BCT Europe operating in the blood & cell technologies company business. Its parent company is one of the significant subsidiaries of the group, which plans to optimize the operations and improve revenue by strengthening strategic production sites in APAC (including Vietnam). For example, the group continued to work on enhancing operations to boost supply capacity, such as by expanding the Vietnam Factory in 2018, 2021.Terumo Corporation – ultimate parent company's shares are listed on TYO under stock code “4543” which major shareholders were The Master Trust Bank of Japan, Ltd – 21.24%, Custody Bank of Japan, Ltd – 9.5%, The Dai-ichi Life Insurance Company, Limited – 4.58% as of September 30, 2022. The group's business activities include cardiac and vascular specialties, hospital products and home health care. The group's revenue by business was blood & cell technologies company – 18% (including it), General Hospital Company – 29% and Cardiac & Vascular Company – 54%.